Related Experiment Videos
Prostacyclin, nitric oxide, and atherosclerosis
R J Gryglewski1, S Chłopicki, J Swies
1Department of Pharmacology, Medical College of Jagiellonian University, Cracow, Poland.
Annals of the New York Academy of Sciences
|January 17, 1995
Summary
Endogenous prostacyclin (PGI2) and nitric oxide (NO) do not interact in arteries. Separate analysis of PGI2 and NO disorders is crucial for understanding atherosclerosis and vascular diseases.
Area of Science:
- Cardiovascular physiology
- Endothelial biology
- Vascular pharmacology
Background:
- Atherosclerosis is associated with impaired production of prostacyclin (PGI2) and nitric oxide (NO).
- Exogenous PGI2 and NO can interact pharmacologically.
- The interaction between endogenous PGI2 and NO within the vascular system is not well understood.
Purpose of the Study:
- To investigate whether endogenous PGI2 and NO interact directly within the vascular intima.
- To determine the distinct roles of endogenous PGI2 and NO in vascular function and disease.
Main Methods:
- Studied mechanisms of cardiac reactive hyperemia in guinea pigs.
- Examined thrombolysis mechanisms in cats.
- Analyzed the release sites of PGI2 and NO in vivo.
Main Results:
- Endogenous PGI2 is released intraluminally by the vascular intima.
- Endogenous NO is secreted abluminally.
- These distinct release sites prevent direct interaction between endogenous PGI2 and NO.
Conclusions:
- Endogenous PGI2 and NO do not interact directly in vivo.
- Disturbances in PGI2 or NO production in disease require separate investigation.
- PGI2 likely maintains endothelial thromboresistance, while NO regulates arterial myocytes and microcirculation.